Advertisement

SABCS 2023: HER2CLIMB-02 Trial in Metastatic HER2-Positive Breast Cancer
Posted: 12/20/2023 | By: Chase Doyle

The HER2CLIMB-02 trial, results of which were presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-10), examined a combination of two HER2-targeted drugs in patients with unresectable locally advanced or metastatic HER2-positive breast cancer.

Question 1 of 5

A previous, related study—the phase II HER2CLIMB trial—led to the approval of which treatment regimen by the U.S. Food and Drug Administration?

Choose 1

A
Tucatinib, trastuzumab, and capecitabine
B
Ado-trastuzumab emtansine (T-DM1) and bevacizumab
C
Tucatinib and imatinib
D
T-DM1 and pembrolizumab

CategoriesView All Quizzes

Tumor Type


Additional Topics



Conference Coverage